DERM - NASDAQ
Journey Medical Corporation
$6.02
+2.0%Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
At a Glance
Live SnapshotJourney Medical Corporation Management Team
Mr. Robert Nevin
Chief Commercial Officer
Mr. Joseph M. Benesch
Chief Financial Officer & Corporate Controller
Compensation
$434,088
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel & Company Secretary
Mr. Louis Donati
Director of Market Access
Dr. Lindsay Allan Rosenwald
Executive Chairman
Compensation
$50,000
Mr. Claude Maraoui
Founder, President, Chief Executive Officer & Director
Compensation
$975,434
Jaclyn Jaffe
Senior Director of Corporate Operations
Journey Medical Corporation Insider Positioning
During the last 12 months, insiders have purchased $1.18M and sold $81K worth of DERM shares, resulting in $1.10M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
187.6K
1.18M
1.3M
81.25K
+1.1M
+$1.10M
Top Buyers
Maraoui Claude
Director, Officer: President & Ceo
$523K
Alloush Ramsey
Officer: Chief Operating Officer
$396K
Benesch Joseph
Officer: Cfo
$264K
Top Sellers
Maraoui Claude
Director, Officer: President & Ceo
$81K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.10M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
DERM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 24, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 25, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 21, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 21, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.